RxDoctor Payments Data

Jeffrey Goldman, MD

Gastroenterology · Traverse City, MINPI 1316039142

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 22 payments — averaging $78.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$560
  • AbbVie$554
  • Gilead$303
  • Sanofi$144
  • Intercept Pharmaceuticals, Inc.$116
  • Medtronic$22
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$1,69198%
  • Education$432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,734 in reported general payments places this provider in the 45th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$52,682
Medicare patients
221
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab19$126,816
LinzessLinaclotide33$26,547
Mesalamine31$21,255
Balsalazide Disodium20$5,074
Omeprazole158$4,430
Dicyclomine Hcl64$3,195
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl89$1,607
Budesonide DrBudesonide16$1,559
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates21$1,488
Pantoprazole Sodium51$1,397
Famotidine52$1,359
Cholestyramine LightCholestyramine12$1,221
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl62$1,117
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg35$929
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl52$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$554$26,54733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →